Search results for "COPD"
Helping more patients quit smoking
Asking patients about smoking and advising them to quit is not enough to set them up for success.
https://immattersacp.org/archives/2022/06/helping-more-patients-quit-smoking.htm
1 Jun 2022
Metoprolol not effective for reducing time to COPD exacerbation
A randomized placebo-controlled trial, which was stopped early due to safety and futility concerns, found no significant between-group difference in median time to first exacerbation of chronic obstructive pulmonary disease (COPD).
https://immattersacp.org/weekly/archives/2019/10/29/4.htm
29 Oct 2019
LABAs, LAMAs for COPD may be associated with increased CVD risk in first 30 days of use
Study authors caution physicians to closely monitor new users of long-acting beta2-agonists (LABAs) or long-acting antimuscarinic antagonists (LAMAs) for cardiovascular symptoms.
https://immattersacp.org/weekly/archives/2018/01/09/4.htm
9 Jan 2018
MKSAP Quiz: Posthospital evaluation for severe COPD
A 64-year-old woman is evaluated during a posthospital visit for severe COPD with an FEV1 of 30% of predicted. She has been admitted three times during the last year with acute exacerbations. Following physical and pulmonary exams, what is the most appropriate treatment to reduce this patient's COPD exacerbations?
https://immattersacp.org/weekly/archives/2019/08/20/3.htm
20 Aug 2019
New COPD treatment, warnings on insomnia and migraine drugs
This regulatory update covers approval of a combined long-term maintenance treatment for chronic obstructive pulmonary disease, warnings against driving after taking insomnia drugs and on use of migraine drugs in pregnant women, and more.
https://immattersacp.org/archives/2013/07/fda.htm
1 Jul 2013
MKSAP Quiz: Routine follow-up for very severe COPD
A 75-year-old man is seen for routine follow-up for very severe COPD. He has constant dyspnea and air hunger and spends most of the day in a chair. He has had no change in baseline cough and sputum production. He has had multiple COPD exacerbations that required ICU admission and intubation. He has not benefited from pulmonary rehabilitation in the past. What is the most appropriate management?
https://immattersacp.org/weekly/archives/2017/11/07/3.htm
7 Nov 2017
New diabetes drug, LABA for COPD, skin antibiotic approved
This update covers approval of a sodium-glucose co-transporter 2 inhibitor for diabetes, a once-daily long-acting beta-adrenergic agonist (LABA) for chronic obstructive pulmonary disease (COPD), and a new intravenous drug for bacterial skin and skin-structure infections.
https://immattersacp.org/archives/2014/10/fda.htm
1 Oct 2014
Guidance on using rapid tests, managing COPD, and screening for cardiac problems in COVID-19
The FDA warned about false positives with rapid tests, guidance addressed care for chronic obstructive pulmonary disease (COPD) during the pandemic, and experts advised on ethics of emergency use authorizations, among other recent COVID-19 news.
https://immattersacp.org/weekly/archives/2020/11/10/1.htm
10 Nov 2020
Triple inhaler therapy associated with reduced COPD exacerbations, higher rates of pneumonia
Results of the systematic review and meta-analysis suggest that triple inhaler therapy should be limited to patients with more severe symptoms of chronic obstructive pulmonary disease (COPD) that cannot be adequately managed by dual therapy, the authors said.
https://immattersacp.org/weekly/archives/2018/11/13/2.htm
13 Nov 2018
New drugs approved for type 2 diabetes and COPD
This regulatory update covers dapaglifozin (Farxiga) a sodium-glucose co-transporter 2 inhibitor, to treat diabetes, and umeclidinium and vilanterol inhalation (Anoro Ellipta) for maintenance of chronic obstructive pulmonary disease.
https://immattersacp.org/archives/2014/03/fda.htm
1 Mar 2014